Explore how political divisiveness impacts mental health and amplifies high-functioning depression, and discover strategies ...

Little information has emerged about osavampator, a potentially first-in-class drug, since its promising Phase II performance last spring.

A team of US-based scientists have found "a probable causal connection" between a form of bacteria found in the human gut and the onset of depression.Carried out by a team from Harvard University and ...

A compelling new study is building on a growing body of evidence showing a common exercise supplement used to build muscle ...

Axsome Therapeutics, Inc. (NASDAQ:AXSM) is a biopharmaceutical company focused on developing novel therapies for central nervous system (CNS) disorders. The company has been gaining significant ...

NeuroStar is committed to advancing the body of scientific research and elevating mental health treatment through robust research and data-driven innovation,” stated Keith J. Sullivan, President and ...

(HealthDay News) — Preventive psychological interventions may be effective for adults with subthreshold depressive symptoms, according to a review published online in the December issue of The Lancet ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

The move expands access to the novel mental health treatment, which has shown rapid symptom improvement for the past few years now.

A new study from the Texas A&M University School of Public Health provides additional evidence that meditation using ...

Neurocrine Biosciences advances Phase 3 plans for osavampator after achieving Phase 2 success in major depressive disorder, amending its Takeda deal.